<DOC>
	<DOCNO>NCT02409849</DOCNO>
	<brief_summary>This phase II study efficacy octreotide lar maintenance treatment first-line chemotherapy patient unresectable metastatic gastro-entero-pancreatic esophageal neuroendocrine carcinoma .</brief_summary>
	<brief_title>Octreotide LAR Maintenance Treatment Patients With NEC</brief_title>
	<detailed_description>This prospective , randomize , open label study efficacy octreotide lar maintenance treatment first-line chemotherapy patient unresectable metastatic gastro-entero-pancreatic esophageal neuroendocrine carcinomas.The patient unresectable metastatic GEP esophageal NEC get CR/PR/SD chemotherapy IP EP regimen qualify inclusion criterion enrol . All patient enrol study randomly assign receive octreotide LAR ( group A ) maintenance treatment follow ( group B ) disease progression . Treatment discontinue withdrawal patient consent , disease progression , unacceptable toxicity , treatment delay &gt; 2 week , major protocol violation , patient follow every 3 month minimum 12 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>1 . Histologic diagnosis high grade ( poorly differentiate ) gastroenteropancreatic neuroendocrine carcinoma . 2 . High grade neuroendocrine carcinoma esophageal unknown primary site ( pulmonary primary exclude ) 3 . Metastatic unresectable disease 4 . Measurable disease 5 . Accepted chemotherapy EP IP regimen less three month 6 . Effectiveness CR/PR/SD 7 . Informed consent 8 . Performance status 0 1 9 . Adequate bone marrow function ( define absolute neutrophil count [ ANC ] &gt; = 1500 , platelet count [ PLT ] &gt; = 75,000 hemoglobin [ Hgb ] &gt; = 9 ) . 10 . Adequate hepatic function bilirubin &lt; = 2.0 mg/dl , aspartate aminotransferase ( AST SGOT ) alanine aminotransferase ( ALT SGPT ) &lt; = 2.5 time upper limit normal , unless cause liver metastasis . If cause metastasis , SGPT SGOT &lt; = 5 time upper limit normal . Adequate renal function define serum creatinine &lt; = 1.5 mg/dl . 1 . Patients EP IP chemotherapy less three month . 2 . Effectiveness PD . 3 . Patients brain metastasis eligible . 4 . Patients New York Heart Association ( NYHA ) Class III IV heart disease eligible well patient history angina , myocardial infarction , congestive heart failure within six month . 5 . Pregnant lactating woman . All woman child bear potential must negative pregnancy test prior entry study . All patient child bear potential must advise importance avoid pregnancy use appropriate method contraception participate investigational trial . 6 . Patients serious complicated infection , nonmalignant medical illness uncontrolled whose control may jeopardize complication therapy . 7 . Patients psychiatric disorder render incapable complying requirement protocol . 8 . Patients serum calcium &gt; 12 mg/dl symptomatic hypercalcemia treatment . 9 . Patients osseous metastasis site disease . 10 . Patients concurrent active malignancy nonmelanoma skin cancer carcinomainsitu cervix . Patients previous malignancy without evidence disease &gt; 5 year allow enter trial . 11 . Patients know Gilbert 's syndrome ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Octreotide LAR</keyword>
	<keyword>Neuroendocrine carcinoma</keyword>
	<keyword>unresectable metastatic</keyword>
	<keyword>Disease-free survival</keyword>
</DOC>